Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




CLND Fails to Improve Melanoma Survival Rates

By HospiMedica International staff writers
Posted on 19 Jun 2017
A new study shows that immediate completion lymph-node dissection (CLND) does not increase survival among patients with melanoma and sentinel-node metastases.

Researchers at the John Wayne Cancer Institute (JWCI; Santa Monica, CA, USA), Sentara CarePlex Hospital (Hampton, VA, USA), and other institutions worldwide conducted a study that randomly assigned 1,934 patients with sentinel-node metastases--detected via standard pathological assessment or a multimarker molecular assay--to immediate CLND or to an observation group monitored with ultrasonography. More...
Main outcomes and measures were melanoma-specific survival, disease-free survival, and cumulative rate of non-sentinel-node metastasis.

The results showed that Immediate CLND was not associated with increased melanoma-specific survival. In the per-protocol analysis, the mean three-year rate of melanoma-specific survival was similar in the dissection group and the observation group (86%) at a median follow-up of 43 months. The mean rate of disease-free survival was slightly higher in the dissection group (68%) than in the observation group (63%) at three years. Lymphedema was observed in 24.1% of the patients in the dissection group and in 6.3% of those in the observation group. The study was published on June 8, 2017, in the New England Journal of Medicine (NEJM).

“Although the completion dissections did not help overall survival, they did have some value. By examining the dissected lymph nodes, physicians were able to better gauge how extensively the cancer had spread and to lengthen the time that their patients were disease-free. But those advantages did not translate into longer lives,” said lead author Mark Faries, MD, of JWCI. “The new findings likely will result in many fewer of these procedures being performed around the world. The results also will likely affect the design of many current and future clinical trials of medical therapies in melanoma.”

Lymph nodes, located throughout the body, serve as biologic filters that contain immune cells that fight infection and clean the blood. When cancer cells break away from a tumor, the cells can travel through the lymph system; sentinel node surgery allows the surgeon to remove the nodes to determine cancer spread. As human nodes are only 5 mm in size, they are difficult to discern from the surrounding tissue during surgery. Furthermore, even when surgeons are able to map the location of the nodes, there is no current technique that indicates whether or not the lymph nodes contain cancer, requiring removal of more lymph nodes than necessary.

Related Links:
John Wayne Cancer Institute
Sentara CarePlex Hospital

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.